• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

止吐研究:方法学探讨

Antiemetic studies: a methodological discussion.

作者信息

Olver I N, Simon R M, Aisner J

出版信息

Cancer Treat Rep. 1986 May;70(5):555-63.

PMID:3708607
Abstract

Methodological issues encountered in reviewing the antiemetic literature are discussed. Variables affecting antiemetic assessment include those relating to the patient, the emetic stimulus, and the differences in action of the antiemetic drugs. Study design questions including the desirability of randomization, double blinding, use of controls, and stratifications for factors such as previous exposure to chemotherapy and strength of the emetic stimulus are discussed. From a statistical viewpoint a parallel subject design with adequate sample size is recommended. The problems of standardizing the evaluation of nausea and vomiting are considered and simple ordinal scales grading severity are suggested. The patient's overall assessment of tolerance of therapy is of primary importance.

摘要

讨论了在回顾止吐文献时遇到的方法学问题。影响止吐评估的变量包括与患者、催吐刺激以及止吐药物作用差异相关的变量。探讨了研究设计问题,包括随机化、双盲、对照的使用以及针对既往化疗暴露和催吐刺激强度等因素的分层的可取性。从统计学角度推荐采用具有足够样本量的平行受试者设计。考虑了恶心和呕吐评估标准化的问题,并提出了简单的按序评分量表来分级严重程度。患者对治疗耐受性的总体评估至关重要。

相似文献

1
Antiemetic studies: a methodological discussion.止吐研究:方法学探讨
Cancer Treat Rep. 1986 May;70(5):555-63.
2
Antiemetic study design: desirable objectives, stratifications and analyses.止吐药研究设计:理想目标、分层与分析。
Br J Cancer Suppl. 1992 Dec;19:S30-3; discussion S33-4.
3
Problems in antiemetic trial design and interpretation.抗呕吐试验设计与解读中的问题。
Oncology (Williston Park). 1989 Aug;3(8 Suppl):5-10.
4
Special feature: in quest of an effective antiemetic in cancer chemotherapy. Research with antiemetics for cancer chemotherapy: problems and possibilities.
Oncol Nurs Forum. 1982 Summer;9(3):11-6.
5
Comparable safety and antiemetic efficacy of a brief (30-second bolus) intravenous granisetron infusion and a standard (15-minute) intravenous ondansetron infusion in breast cancer patients receiving moderately emetogenic chemotherapy.在接受中度致吐性化疗的乳腺癌患者中,短暂(30秒推注)静脉注射格拉司琼与标准(15分钟)静脉注射昂丹司琼的安全性和止吐疗效相当。
Cancer J Sci Am. 1998 Jan-Feb;4(1):52-8.
6
Nurses' perceptions of antiemetic effectiveness.护士对抗呕吐药物疗效的看法。
Oncol Nurs Forum. 1995 Sep;22(8):1243-52.
7
Double-blind crossover trial of droperidol, metoclopramide, and prochlorperazine as antiemetics in cisplatin therapy.
Clin Pharm. 1984 Nov-Dec;3(6):618-21.
8
[Improvement in the control of chemotherapy induced emesis with ondansetron, methylprednisolone and lorazepam combination in patients treated by a moderate emetic treatment and uncontrolled by a previous antiemetic combination].
Bull Cancer. 2000 Jun;87(6):491-7.
9
Employment of substandard antiemetic prophylaxis in recent trials of chemotherapy-induced nausea and vomiting.
Ann Pharmacother. 2005 Nov;39(11):1903-10. doi: 10.1345/aph.1G079. Epub 2005 Oct 4.
10
Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America.在标准止吐治疗中添加神经激肽1受体拮抗剂阿瑞匹坦可改善对化疗引起的恶心和呕吐的控制。拉丁美洲一项随机、双盲、安慰剂对照试验的结果。
Cancer. 2003 Jun 15;97(12):3090-8. doi: 10.1002/cncr.11433.

引用本文的文献

1
A systematic review of methodologies, endpoints, and outcome measures in randomized trials of radiation therapy-induced nausea and vomiting.放射治疗引起的恶心和呕吐随机试验中方法、终点和结局指标的系统评价。
Support Care Cancer. 2017 Jun;25(6):2019-2033. doi: 10.1007/s00520-017-3685-9. Epub 2017 Mar 31.
2
Dexamethasone improves the efficacy of granisetron in the first 24 h following high-dose cisplatin chemotherapy.地塞米松可提高格拉司琼在大剂量顺铂化疗后最初24小时内的疗效。
Support Care Cancer. 1995 Sep;3(5):307-12. doi: 10.1007/BF00335307.
3
Methodological issues in antiemetic studies.
止吐研究中的方法学问题。
Invest New Drugs. 1993 Nov;11(4):243-53. doi: 10.1007/BF00874423.
4
Inconsistency of prognostic factors for post-chemotherapy nausea and vomiting.化疗后恶心呕吐预后因素的不一致性。
Support Care Cancer. 1994 May;2(3):161-6. doi: 10.1007/BF00417474.
5
Acupuncture prophylaxis of cancer chemotherapy-induced sickness.针灸预防癌症化疗引起的恶心呕吐。
J R Soc Med. 1989 May;82(5):268-71. doi: 10.1177/014107688908200508.
6
Assessment of nausea.恶心的评估。
Eur J Clin Pharmacol. 1990;38(2):115-20. doi: 10.1007/BF00265968.
7
Double-blind, randomized crossover study of metoclopramide and batanopride for prevention of cisplatin-induced emesis.甲氧氯普胺和巴氯必利预防顺铂所致呕吐的双盲随机交叉研究
Cancer Chemother Pharmacol. 1991;28(3):226-7. doi: 10.1007/BF00685516.
8
Controlling cancer chemotherapy-induced emesis. An update.控制癌症化疗引起的呕吐。最新进展。
Pharm Weekbl Sci. 1991 Oct 18;13(5):189-97. doi: 10.1007/BF01988874.
9
Continuous infusion of high-dose metoclopramide: comparison of pharmacokinetically adjusted and standard doses for the control of cisplatin-induced acute emesis.大剂量胃复安持续输注:比较药代动力学调整剂量与标准剂量对顺铂所致急性呕吐的控制效果
Eur J Clin Pharmacol. 1991;40(3):283-6. doi: 10.1007/BF00315210.
10
Antiemetic study design: desirable objectives, stratifications and analyses.止吐药研究设计:理想目标、分层与分析。
Br J Cancer Suppl. 1992 Dec;19:S30-3; discussion S33-4.